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Background: The treatment options for hydatid cyst liver include non-operative and operative methods.
Operative methods include conservative and radical procedures. Non-operative methods include
chemotherapy and percutaneous treatment of liver hydatidosis.
Material and methods: The study was conducted at Sher-i-Kashmir Institute of Medical Sciences, Soura,
Srinagar, Kashmir, India, over a period of two years from March 2001 to February 2003 with further
follow-up of 5–6 years. The study included 64 cases in the age group of 15 years to 64 years, comprising
36 males and 28 females. The aim of the study was to know the effect of preoperative and postoperative
albendazole therapy on the viability of protoscolices and recurrence rate of hydatid disease of liver.
Patients were divided into four group of 16 each. In group A, patients were directly subjected to surgery.
In group B, patients were given albendazole for 8 weeks followed by surgery. In group C, patients were
given albendazole for 8 weeks preoperatively followed by further postoperative course for 8 weeks. In
group D, patients were ﬁrst taken for surgery followed by postoperative course of albendazole for 8
weeks.
Results: Out of those patients who received preoperative albendazole only 9.37% had viable cysts at the
time of surgery as compared to 96.87% of patients who did not receive any preoperative albendazole. In
those patients who did not receive any albendazole therapy, recurrence rate was 18.75% whereas
recurrence was 4.16% in patients who received albendazole therapy.
Conclusion: We conclude that albendazole is safe and effective adjuvant therapy in the treatment of
hydatid liver disease.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Echinococcosis or hydatidosis or hydatid disease is the most
frequent cause of liver cysts in the world.1 The prevalence of
hydatid cyst in humans appears to be directly related to a low level
of sanitation. The disease is prominent in rural areas with poor
housing conditions, where humans, dogs and cattle exist in close
proximity.2,3
The majority of patients with hydatid liver disease have indolent
presentation and are otherwise healthy. 75% cases present with an
asymptomatic abdominal mass.4 The symptomatic patients most
common complain of mild to moderate right upper quadrant pain.
Acute, severe abdominal pain does occur occasionally and usually indi-
cates rupture, biliary complications and secondary bacterial infection.5em Bagh, Hazratbal, Srinagar,
s-ul-Bari).
ciates Ltd. Published by Elsevier LtUltrasonography has the best diagnostic efﬁciency because it
can be used to recognize cysts as small as 1 cm in diameter.1 CT has
a sensitivity of 100% in detecting liver cyst approach and helps in
accurate anatomic localization of cysts.4 Number of serological tests
have been used for diagnosis of hydatid disease. Among them ELISA
is the most widely used.6
Treatment options for hydatid cyst of liver include non-operative
and operative methods. Non-operative methods include chemo-
therapy and percutaneous treatment of liver hydatidosis. Operative
methods include conservative and radical procedures (Figs.1 and 2).
Chemotherapy has been used as an adjuvant to surgical treat-
ment either preoperatively or postoperatively or both. A short
course of chemotherapy after surgery reduces the risk of recurrence
and preoperative therapy sterilizes the cysts and reduces their
tension, making surgery easier.
Bekhti et al. (1977) were the ﬁrst to report successful results of
chemotherapy of hydatid disease using membendazole.7 Alben-
dazole is another benzimidazole carbamate with better absorption
properties. It has been seen that its metabolite albendazoled. All rights reserved.
Fig. 1. Photomicrograph (high power) of cyst aspirate showing liver protoscolex – able
to exclude 5% eosin.
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in in vitro cultures and it is able to penetrate into hydatid cysts.8
Comparative assessment of the therapeutic effect of two drugs has
favoured albendazole.
2. Material and methods
This study was conducted jointly by the departments of General
Surgery and Gastroenterology, Sher-i-Kashmir Institute of Medical
Sciences, Srinagar, Kashmir on all the patients admitted with
diagnosis of hydatid liver from March 2001 to February 2003, with
further follow-up for another 5–6 years. The aim of our study was
to assess the effect of preoperative albendazole therapy on the
viability of protoscolices at the time surgery and the effect of
preoperative and/or postoperative use of albendazole on the
recurrence rate of hydatid disease of liver. The conﬁrmation in
every case was done by demonstrating hydatid materialdsand,
hooklets, protoscolices or daughter cysts at the time of surgery.
Patients were included in the study after informed written
consent. Patientswere excluded if, a) the cystwas infected, b) the cyst
had ruptured into the biliary tree, pleural cavity orperitoneal cavityc)Fig. 2. Photomicrograph (high power) of cyst aspirate showing dead protoscolex –
stained with 5% eosin.the cyst was densely calciﬁed (type V cyst), d) the cyst had
associated extrahepatic cysts, e) the cysts were multiple and f)
the patient was a married woman who was pregnant or
intended to conceive during the study period.
After entry into the study, the 64 patients were stratiﬁed into
the types of hydatid cyst (type I and II vs type III and IV) and were
randomized into four groups in a recurring block of four as follows:
In the group A (n¼ 16) patients were subjected to surgery (surgery
group). In group B (n¼ 16) patients were given albendazole for 8
weeks and were subsequently operated upon (preoperative
albendazole group). In group C (n¼ 16) patients were given
albendazole for 8 weeks preoperatively followed by further course
of albendazole for 8 weeks postoperatively (pre- and postoperative
albendazole group). In group D (n¼ 16) patients underwent
surgery followed by 8-week-course of albendazole in the post-
operative period (postoperative albendazole group).
All patients after entry into the study underwent a detailed
history, physical and systemic examination. All the patients were
subjected to detailed investigations like haemogram, kidney func-
tion test, liver function test, coagulogram, electrocardiography and
X-ray chest. Ultrasonography was the main tool for diagnosis. All
patients were subjected to ELISA for hydatidosis. CT abdomen was
performed in those cases where results of ultrasonography were
equivocal. Patientswere given albendazole at a dose of 10 mg/kg/day
in divided doses. All patients were initially monitored weekly
and thereafter monthly by liver function test, kidney function
tests, white cell and platelet counts and urine analysis.
A right subcostal approach was used in all patients for surgical
intervention. The steps of surgery included scolicidal irrigation, and
cyst evacuation followed by external tube drainage.
Cyst contents were collected in all the cases for cytological
and bacteriological examination. The cyst ﬂuid was centrifuged and
examined for the fragments of laminated membrane, hooklets and
scolices. Viability assessment of the cysts was performed by
observing the motility of the scolices and their ability to exclude 5%
eosin, under immediate microscopy. Scolices which were motile
and did not stainwith eosinwere considered live while the scolices
whichwere immotile and stainedwith eosinwere considered dead.
The other factors which suggest that the cyst is viable include ovoid
form, invaginated scolices and intact calcareous corpuscles and
presence of vibrating movements. Fertility was deﬁned as living
protoscolices in relation to the total number of protoscolices.
All operative and postoperative complications were recorded.
All patients were followed up initially every month for three
months, and thereafter every three months for one year and
subsequently every six months. Ultrasonography was done at every
visit and cyst diameter, volume and cyst pattern was recorded.
During ultrasonographic examination other abdominal organs
were examined to exclude recurrent cyst formation. Radiograph of
chest was done at 6months intervals to look for any hydatid disease
in the lung. Hydatid serology IgG and IgM by ELISA was done every
six months.
In addition to descriptive statistics, the standard statistical
methods were used for data analysis. These included the Student’s
t-test and the chi-square test. A p value of <0.05 was taken as the
criterion of statistical signiﬁcance.3. Results and observation
The present study comprised of 64 cases of hydatid cyst liver.
There were 36 (56.25%) males and 28 (43.75%) females with a male
to female ratio of 1.3:1 (Table 1). The mean age of the patients was
36.7711.45 years. Majority of the patients were in the age group
of 25–44 years 46 (71.87%) patients belonged to rural areas while
the remaining 18 (28.13%) belonged to urban areas.
Table 1
Age and sex distribution of the study population (n¼ 64)
Number Males, 36 Females, 28 Overall, 64
Age (yrs) Mean 36.75 36.78 36.77
þSD 11.34 11.79 11.45
Range 15–64 16–62 15–64
Table 3
Comparison of cyst viability in different study groups as determined by scolices
motility and ability to exclude 5% eosin
Study groups Viable no. (%) Non-viable no. (%)
Group A (n¼ 16) 16 (100) 0 (0)
Group B (n¼ 16) 1 (6.25) 15 (93.75)
Group C (n¼ 16) 2 (12.5) 14 (87.5)
Group D (n¼ 16) 15 (93.75) 1 (6.26)
X2df3 ¼ 49.44; p< 0.01.
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type I hydatid cysts. Type II hydatid cysts were found in 25% of the
cases followed by type III in 14% of cases and type IV hydatid cysts
in 6.25% cases (Table 2).
All the patients in group A i.e., surgery only group and 93.75% of
patients in group D i.e. postoperative albendazole group had viable
protoscolices at the time of surgery, whereas only 6.25% of patients
in group B (preoperative albendazole group) and 12.50% of patients
in group C (pre- and postoperative albendazole group) had viable
protoscolices at the time of surgery (Table 3). All the patients in
groups B and C with viable cyst had multiple daughter cysts in the
main cyst.
Out of 32 patients who received preoperative albendazole
(groups B and C), only 3 (9.37%) patients had viable protoscolices at
the time of surgery, whereas in patients who did not receive any
preoperative albendazole therapy, 31 (96.87%) had viable proto-
scolices at the time of surgery (Table 4). Patients who had received
preoperative albendazole therapy had signiﬁcantly lower
percentage of viable cysts at the time of surgery (p< 0.01).
In our series of 64 operated patients, 3 (18.25%) patients in
group A developed postoperative recurrence, whereas none of the
patients from group C developed recurrence. One (6.25%) patient
each from groups B and D developed postoperative recurrence in
the mean follow-up period 5–6 years (Table 5).
Out of 48 patients who received albendazole therapy (pre- and/
or postoperative therapy), only 2 (4.16%) patients had recurrence of
the diseases whereas out of 16 who did not receive any albendazole
therapy 3 (18.75%) patients, had recurrent disease (Table 6).
Patients who had received albendazole therapy had signiﬁcantly
lower recurrence (p< 0.01).
4. Discussion
Hydatidosis is the commonest human larval cestodiasis. Liver is
the most common site of involvement.1 The mainstay of treatment
of hepatic hydatid disease is surgery.1 Medical therapy of hydati-
dosis has been tried with many drugs including benzimidazole
carbamate group. Mebendazole was the ﬁrst drug to be used for
hydatid disease. Later on albendazole was introduced with better
absorption properties. Albendazole given preoperatively in dose of
10 mg/kg/day for 1 month causes sterilization of the hepatic
hydatid cyst, killing most of the protoscolices. However, high
effectiveness of albendazole as liver cyst therapy has been reported
after three months of uninterrupted treatment.9 The usual dosage
scheme for albendazole, suggested by Horton (1989) and endorsed
by WHO is, three 28 day courses of 10 mg/kg/day in divided doses
separated by two weeks intervals.10 These benzimidazole carba-
mate groups of drugs act by blocking glucose uptake in the parasite
and depletion of its glycogen stores.Table 2
Types of hydatid cysts in different groups (n¼ 64)
Type n (%)
Total Group A Group B Group C Group D
Type I 30 (46.88) 8 (26.66) 9 (30.00) 7 (23.33) 6 (20.00)
Type II 16 (25.00) 5 (31.25) 4 (25.00) 3 (18.75) 4 (25.00)
Type III 14 (21.87) 2 (14.28) 1 (7.14) 6 (24.85) 5 (35.71)
Type IV 4 (6.25) 1 (25.00) 2 (50.00) – 1 (25.00)Praziquental is another class of drugs used against hydatid cyst
liver disease. It is the most active and rapid scolicidal agent. Its
effect on the germinal layers is much less than on protoscolices.
Praziquental is probably the ideal agent for prophylaxis in the
preoperative and postoperative setting to prevent implantation of
protoscolices and subsequent recurrence. It is unlikely to be as
effective as albendazole in treating whole cyst.
Chemotherapy is effective in small cysts less than 4 cm in
diameter, cyst with thin walls and in younger patients. It is indi-
cated in patients who are at high risk for surgery, in patients with
multiple peritoneal cysts, cysts in multiple organs, bone cysts, cyst
in brain, to prevent secondary echinococcosis after spillage during
surgery and as a concomitant therapy with percutaneous drainage.
Recently, percutaneous drainage of hydatid cysts, popularly
known as PAIR (puncture, aspiration, installation of scolicidal agent
and respiration) technique has gained acceptance.10,11
A prospective study was undertaken to assess the utility of
albendazole as add-on therapy to the standard surgical manage-
ment of hydatid disease of liver. Albendazole used in the dose of
10 mg/kg in divided doses as an adjuvant therapy to surgical
treatment signiﬁcantly improved the results in 48 patients out of
64.
Preoperative use of albendazole was associated with a signiﬁ-
cantly decreased rate of cyst viability at the time of surgery, as was
assessed by the motility of the scolices and their ability to exclude
5% eosin under immediate microscopy. Of those patients who
received preoperative albendazole for 2 months only 9.37% had
viable cysts at the time of surgery as compared to 96.87% of patients
who did not receive any preoperative albendazole therapy. This
decrease in cyst viability was statistically signiﬁcant (p< 0.01) and
indicates that two months preoperative course of albendazole kills
most of protoscolices within hydatid cysts.
Our observations are in agreement with some previous studies.
Morris (1987) treated 16 patients with preoperative albendazole
10 mg/kg/day for a variable period of one week to one month. Out
of the 14 patients who received albendazole for 1 month or more
before operation, only one had viable protoscolices. In contrast,
each of the two remaining patients who received only one and
three weeks’ therapy had liver disease at the time of operation.12
Out of the patients who received preoperative albendazole in
our study, only 3 patients had viable cysts and in all these three
patients, cysts contained multiple daughter cysts. Protoscolices in
the main cyst were dead, whereas in daughter cysts, they were
viable. It seems that preoperative albendazole while being
successful in eradicating the hydatid parasites inside the mother
cyst is not fully effective in treating the scolices inside the daughterTable 4
Comparison of the cyst viability in the patients who received preoperative alben-
dazole therapy vs those who did not receive any preoperative albendazole therapy
Group Number Viability
No %
B and C 32 3 9.37
A and D 32 31 96.87
X2df1 ¼49.19; p< 0.01.
Table 5
Comparison of recurrence in different study group
Study groups Follow-up (yrs) Recurrence
No. %
A (n¼ 16) 3–4 3 18.25
B (n¼ 16} 3–4 1 6.25
C (n¼ 16) 3–4 0 0
D (n¼ 16) 3–4 1 6.25
p value: group A vs group B¼NS; group A vs group C¼NS; group Avs group D¼NS;
group A vs groups B and C¼<0.05.
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shielded within the mother cyst. In group B there was only one
patient while in group C, there were 2 patients with multiple
daughter cysts within the main cyst, hence the low prevalence of
viable cysts in group B, as compared to group C. Carlos Manterola
et al.13 conducted a study to determine the plasmatic and intra-
cystal concentration of albendazole sulfoxide and correlate them
with the viability of the scolices in surgically treated patients who
had received albendazole preoperatively. A total of 26 patients
were studied and were given 10 mg/kg/day of albendazole for 4
days prior to the surgery. Plasma concentration and intracystal
concentration of albendazole sulfoxide weremeasured bymeans of
high performance liquid chromatography. The variables which
were taken into concentration included diameter, type of cyst,
number of cyst and development of cysto-billiary communications.
They found no association between intracystal level of albendazole
sulfoxide and the viability of scolices.
Horton (1989) treated 500 patients with 800 mg of albendazole
daily in cycles of 28 days with a drug free interval of 14 days
between the cycles for a mean duration of 2.5 cycles. Two hundred
and ﬁfty-three patients were evaluated for efﬁcacy. After treatment
47 patients underwent surgery and viability was demonstrated in
only 5 (10.6%) patients.14 Recurrence rate of 18.75% was noticed
over a follow-up period of 5–6 months in the patients who did not
receive any albendazole, whereas preoperative (pre- and/or post-
operative) use of albendazole was found to signiﬁcantly reduce the
risk of recurrence to 4.16%. These observations are in general
agreement with previously published data. Mottaghlan and Saidi
(1979) observed recurrence of 11.3% over a period of 6 months to 3
years in a study comprising 106 patients.15 Little et al. (1988)
observed a recurrence of 22% in his study.16 Morris in 1989
observed no recurrence in patients treated with preoperative
albendazole for one month with a median postoperative follow-up
of 28 months.17
In our study, patients who received both preoperative and
postoperative albendazole, there was no recurrence in any of the 16
patients followed postoperatively for a period of 5–6 years. This is
in agreement with the observations made by Evangelos et al., who
treated 67 patients of liver hydatidosis with preoperative meben-
dazole in the dose of 40 mg/kg/day (18 patients) or albendazole in
the dose of 10 mg/kg/day in 49 patients for 5 days before surgery
followed by one month course of same benzimidazole in patients
with viable protoscolices at the time of surgery. None of theseTable 6
Comparison of recurrence in patients who received pre- and/or postoperative
albendazole therapy (groups B, C and D) vs those who did not receive any alben-
dazole therapy (group A)
Group Number Recurrence (% age)
A 16 3 (18.75)
BCD 48 2 (4.16)
X2dfl ¼ 25.04; p< 0.01.patients had any recurrence of disease after a follow-up of 15–67
months (average 41 months).18
All patients treated with albendazole 10 mg/kg/day in two
equally divided doses tolerated the drug without any severe
untoward symptom. Mild abdominal pain, nausea and vomiting
were observed in 4% of patients. Reversible alopacia was seen in 4%
patients. One patient had abnormally low white cell count while
receiving albendazole. It was not progressive despite continuing
therapy. Asymptomatic liver function test abnormalities were
observed in 16% of patients after albendazole therapy but returned
to normal levels within a month of therapy. Mild anemia (Hb< 9 g/
dl) was observed in one patient and remained stable over the
duration of albendazole therapy. These observations are in agree-
ment with the study conducted by Morris (1988)12 and Horton
(1989).144. Conclusion
We conclude that albendazole is safe and effective adjuvant
therapy in the management of hepatic hydatidosis in addition to
the standard surgical treatment. Preoperative use of albendazole
for two months signiﬁcantly decreases the chances of cyst viability
at the time of surgery. Postoperative use of albendazole for two
months also decreases the chances of cyst recurrence. Combined
pre- and postoperative albendazole use for a total of four months is
highly effective in reducing the chances of the preoperative cyst
viability as well as the postoperative cyst recurrence. Such
combined pre- and postoperative use of albendazole may be
superior to the use of the drug either preoperatively or
postoperatively.References
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